From the Analyst's Couch |
From the Analyst's Couch
-
-
From the Analyst's Couch |
Trends in oncology drug innovation in China
- Guanqiao Li
- , Yunhe Qin
- , Cuicui Xie
- , Yi-Long Wu
- & Xiaoyuan Chen
-
From the Analyst's Couch |
The failure to fail smartly
- Steven Galson
- , Christopher P. Austin
- , Eeshan Khandekar
- , Lynn D. Hudson
- , Joseph A. DiMasi
- , Robert Califf
- & John A. Wagner
-
From the Analyst's Couch |
Immuno-oncology drug development forges on despite COVID-19
- Samik Upadhaya
- , Vanessa M. Hubbard-Lucey
- & Jia Xin Yu
-
From the Analyst's Couch |
Evolution of the COVID-19 vaccine development landscape
- Tung Thanh Le
- , Jakob P. Cramer
- , Robert Chen
- & Stephen Mayhew
-
From the Analyst's Couch |
Developing blockbuster drugs: both nature and nurture
- Lotte Berghauser Pont
- , Jiri Keirsse
- , Rachel Moss
- , Pawel Poda
- , Lucas Robke
- & Stephan Wurzer
-
From the Analyst's Couch |
Cancer cell therapies: the clinical trial landscape
- Jia Xin Yu
- , Samik Upadhaya
- , Revati Tatake
- , Fern Barkalow
- & Vanessa M. Hubbard-Lucey
-
From the Analyst's Couch |
RNA therapeutics on the rise
- Feng Wang
- , Travis Zuroske
- & Jonathan K. Watts
-
From the Analyst's Couch |
Breaking Eroom’s Law
- Michael S. Ringel
- , Jack W. Scannell
- , Mathias Baedeker
- & Ulrik Schulze
-
From the Analyst's Couch |
The COVID-19 vaccine development landscape
- Tung Thanh Le
- , Zacharias Andreadakis
- , Arun Kumar
- , Raúl Gómez Román
- , Stig Tollefsen
- , Melanie Saville
- & Stephen Mayhew
-
From the Analyst's Couch |
The small-cell lung cancer drug market
- Joshua B. N. Dawkins
- & Rachel M. Webster
-
From the Analyst's Couch |
Tumour-agnostic therapies
- Ann-Marie Looney
- , Khurram Nawaz
- & Rachel M. Webster
-
-
From the Analyst's Couch |
Trends in clinical development for PD-1/PD-L1 inhibitors
- Jia Xin Yu
- , Jeffrey P. Hodge
- , Cristina Oliva
- , Svetoslav T. Neftelinov
- , Vanessa M. Hubbard-Lucey
- & Jun Tang
-
From the Analyst's Couch |
Immuno-oncology drug development goes global
- Jia Xin Yu
- , Vanessa M. Hubbard-Lucey
- & Jun Tang
-
From the Analyst's Couch |
The acute myeloid leukaemia market
- Jorrit Schaefer
- , Sorcha Cassidy
- & Rachel M. Webster
-
From the Analyst's Couch |
The global pipeline of cell therapies for cancer
- Jia Xin Yu
- , Vanessa M. Hubbard-Lucey
- & Jun Tang
-
From the Analyst's Couch |
Trends in clinical success rates and therapeutic focus
- Helen Dowden
- & Jamie Munro
-
From the Analyst's Couch |
Non-Hodgkin lymphoma therapy landscape
- Kritika Chaudhari
- , Salman Rizvi
- & Basharut A. Syed
-
From the Analyst's Couch |
The fragmentation of biopharmaceutical innovation
- Katarzyna Smietana
- , David Quigley
- , Bart Van de Vyver
- & Martin Møller
-
-
From the Analyst's Couch |
Unlocking the power of translational medicine
- Matthias Evers
- , Martin Møller
- , Ivan Ostojic
- , Valentina Sartori
- & Weina Wang
-
From the Analyst's Couch |
Gene therapies in ophthalmic disease
- Kathleen Gordon
- , Amy Del Medico
- , Ian Sander
- , Arvind Kumar
- & Bashar Hamad
-
-
From the Analyst's Couch |
Demystifying industry–academia collaboration
- Thomas Gersdorf
- , Vivianna Fang He
- , Ann Schlesinger
- , Guido Koch
- , Dominic Ehrismann
- , Hans Widmer
- & Georg von Krogh
-
-
-
From the Analyst's Couch |
Trends in the global immuno-oncology landscape
This report analyses the dramatic progress in the global immuno-oncology landscape from September 2017 to September 2018.
- Jun Tang
- , Laura Pearce
- , Jill O'Donnell-Tormey
- & Vanessa M. Hubbard-Lucey
-
From the Analyst's Couch |
Reforming China's drug regulatory system
Since 2015, the Chinese government has introduced numerous reforms with the aim of establishing a more scientific and efficient drug regulatory system, which are highlighted here.
- Lili Xu
- , Huijun Gao
- , Kenneth I. Kaitin
- & Liming Shao
-
From the Analyst's Couch |
The hepatocellular carcinoma market
The market for hepatocellular carcinoma is set to change with the recent approvals of the kinase inhibitor lenvatinib and the immune checkpoint inhibitor nivolumab, as well as the anticipated approvals of further immunotherapies.
- Joshua Dawkins
- & Rachel M. Webster
-
From the Analyst's Couch |
Trends driving clinical trials into large clinical care settings
This analysis highlights data indicating the limitations of traditional clinical trial processes, and discusses how moving clinical trials into large clinical care settings could help meet the growing demands for large volumes of sophisticated patient data.
- Kenneth Getz
-
From the Analyst's Couch |
The market for oral anticoagulants
This article discusses the market for oral anticoagulants, and how therapies in development and antidotes to existing drugs could affect the therapeutic landscape.
- Stephen Bielecki
- , Dolim Lee
- & Bashar Hamad
-
From the Analyst's Couch |
The global landscape of cancer cell therapy
How many cancer cell therapies are being developed? To harmonize efforts in this arena, the Cancer Research Institute has curated a database that includes all cell therapies in development.
- Jun Tang
- , Vanessa M. Hubbard-Lucey
- , Laura Pearce
- , Jill O'Donnell-Tormey
- & Aiman Shalabi
-
From the Analyst's Couch |
The haemophilia drug market
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.
- Kerri Brown
- & Graeme Green
-
From the Analyst's Couch |
What drives site performance in clinical trials?
This article highlights results from a comprehensive study of the performance of clinical trial sites, which could help companies understand the underlying drivers of success.
- Brendan Smith
- , Linda Martin
- , Scott Martin
- , Maria Denslow
- , Melissa Hutchens
- , Conrad Hawkins
- , Valery Panier
- & Michael S. Ringel
-
From the Analyst's Couch |
The gastroesophageal cancer drug market
Immune checkpoint inhibitors are forecast to expand the market for gastroesophageal cancer drugs, which is particularly large in Asia.
- Paul Wilcock
- & Rachel M. Webster
-
From the Analyst's Couch |
Biopharma deal-making in 2017
This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2017, highlighting trends and major deals.
- Amanda Micklus
- & Steven Muntner
-
From the Analyst's Couch |
The market for chimeric antigen receptor T cell therapies
This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematological malignancies.
- Amy Yip
- & Rachel M. Webster
-
From the Analyst's Couch |
The atopic dermatitis market
The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development.
- Eleni Pantazi
- , Gianluca Valenza
- , Manuela Hess
- & Bashar Hamad
-
From the Analyst's Couch |
Biomarker strategy in lung cancer
This article discsusses how biomarkers will continue to change the market for non-small-cell lung cancer.
- Mine Esencay
- , Andrew Watson
- , Kaushiki Mukherjee
- , Delphine Hanicq
- & Steven I. Gubernick
-
From the Analyst's Couch |
The human microbiome: opportunity or hype?
This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models.
- Pedro M. Valencia
- , Magali Richard
- , Jesse Brock
- & Elsy Boglioli
-
From the Analyst's Couch |
Pulling away from the pack in drug launches
This analysis of US drug launches from the past decade indicates that commercial success has become more difficult to achieve, owing to factors such as increased competition, greater challenges in achieving therapeutic differentiation and payer pressures.
- Nicholas Donoghoe
- , Jon Duane
- , Jin Kim
- & George Xu
-
From the Analyst's Couch |
What is the right amount to spend on biopharma R&D?
This analysis investigates whether some companies may be negatively affecting their overall commercial success by aiming to maintain steady earnings per share growth and/or a target ratio of R&D spending to sales.
- Michael S. Ringel
-
From the Analyst's Couch |
The multiple sclerosis market
This article discusses the impact of new drugs on the market for multiple sclerosis, including the recently approved immunomodulatory drug ocrelizumab and drugs in development such as sphingosine 1-phosphate receptor modulators and neurorestorative agents.
- Anders Westad
- , Aditya Venugopal
- & Eric Snyder
-
From the Analyst's Couch |
The ovarian cancer drug market
This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.
- Jennifer Bamford
- & Rachel M. Webster
-
From the Analyst's Couch |
How much do clinical trials cost?
This article presents the findings of a recent analysis of the costs of clinical trials, providing benchmark data for companies to assess their performance, as well as indicating cost drivers.
- Linda Martin
- , Melissa Hutchens
- , Conrad Hawkins
- & Alaina Radnov
-
From the Analyst's Couch |
Colorectal cancer drugs market
The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.
- Sorcha Cassidy
- & Basharut A. Syed
-
From the Analyst's Couch |
Trends in the market for antihypertensive drugs
This analysis provides an overview of novel antihypertensive products, many of which are fixed-dose combinations of different drug classes, and provides an outlook on their likely impact on the market.
- M. Adam Ali
- , Salman Rizvi
- & Basharut A. Syed
-
From the Analyst's Couch |
Biopharma deal-making in 2016
This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2016, highlighting trends and major deals.
- Amanda Micklus
- & Steven Muntner
-
From the Analyst's Couch |
The immuno-oncology race: myths and emerging realities
This article analyses the huge volume of clinical trial activity for immune checkpoint inhibitors, and discusses the development of the market and strategic trends for immuno-oncology therapies in general.
- Stephen Cavnar
- , Pedro Valencia
- , Jesse Brock
- , Judith Wallenstein
- & Valery Panier